Molecular mechanisms of T cell co-stimulation and co-inhibition

Nature Reviews Immunology

Volumn 13, Issue 4, 2013, Pages 227-242

  Chen, Lieping ^a   Flies, Dallas B ^a,b  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HERMES ANTIGEN; INTERLEUKIN 4; LEUKOSIALIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CDC42; PROTEIN KINASE B; PROTEIN KINASE C EPSILON; PROTEIN P50; SYNAPTOTAGMIN I; T LYMPHOCYTE RECEPTOR; TALIN; TRANSCRIPTION FACTOR C MAF; TRANSCRIPTION FACTOR NFAT;

APOPTOSIS; CELL SURVIVAL; CELL TYPE; CYTOKINE PRODUCTION; EFFECTOR CELL; ENDOCYTOSIS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; MOLECULAR MECHANICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84875463042     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3405     Document Type: Review

References (134)

1. June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T. & Thompson, C. B. Tcell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell. Biol. 7, 4472-4481 (1987). (Pubitemid 17166404)
2. Bretscher, P. & Cohn, M. A theory of self-nonself discrimination. Science 169, 1042-1049 (1970).
3. Mueller, D. L., Jenkins, M. K. & Schwartz, R. H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7, 445-480 (1989). (Pubitemid 19138020)
4. Liechtenstein, T., Dufait, I., Lanna, A., Breckpot, K. & Escors, D. Modulating costimulation during antigen presentation to enhance cancer immunotherapy. Immunol. Endocr. Metab. Agents Med. Chem. 12, 224-235 (2012).
5. Saito, T., Yokosuka, T. & Hashimoto-Tane, A. Dynamic regulation of T cell activation and costimulation through TCR-microclusters. FEBS Lett. 584, 4865-4871 (2010).
6. Greenwald, R. J., Freeman, G. J. & Sharpe, A. H. The B7 family revisited. Annu. Rev. Immunol. 23, 515-548 (2005). (Pubitemid 40563179)
7. Gonzalez, L. C. et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc. Natl Acad. Sci. USA 102, 1116-1121 (2005). (Pubitemid 40170735)
8. Sedy, J. R. et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nature Immunol. 6, 90-98 (2005). (Pubitemid 40136700)
9. Brandt, C. S. et al. The B7 family member B7H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495-1503 (2009).
10. Chattopadhyay, K. et al. Sequence, structure, function, immunity: structural genomics of costimulation. Immunol. Rev. 229, 356-386 (2009).
11. Kane, L. P. T cell Ig and mucin domain proteins and immunity. J. Immunol. 184, 2743-2749 (2010).
12. Bierer, B. E., Peterson, A., Gorga, J. C., Herrmann, S. H. & Burakoff, S. J. Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor. J. Exp. Med. 168, 1145-1156 (1988).
13. Cannons, J. L., Tangye, S. G. & Schwartzberg, P. L. SLAM family receptors and SAP adaptors in immunity. Annu. Rev. Immunol. 29, 665-705 (2011).
14. Bengsch, B. et al. Coexpression of PD1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 6, e1000947 (2010).
15. Kageyama, R. et al. The receptor Ly108 functions as a SAP adaptor-dependent onoff switch for T cell help to B cells and NKT cell development. Immunity 36, 986-1002 (2012).
16. Zhao, F., Cannons, J. L., Dutta, M., Griffiths, G. M. & Schwartzberg, P. L. Positive and negative signaling through SLAM receptors regulate synapse organization and thresholds of cytolysis. Immunity 36, 1003-1016 (2012).
17. Schwartzberg, P. L., Mueller, K. L., Qi, H. & Cannons, J. L. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nature Rev. Immunol. 9, 39-46 (2009).
18. Arnett, H. A., Escobar, S. S. & Viney, J. L. Regulation of costimulation in the era of butyrophilins. Cytokine 46, 370-375 (2009).
19. Sierro, S., Romero, P. & Speiser, D. E. The CD4like molecule LAG3, biology and therapeutic applications. Expert Opin. Ther. Targets 15, 91-101 (2011).
20. Chan, C. J., Andrews, D. M. & Smyth, M. J. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. Curr. Opin. Immunol. 24, 246-251 (2012).
21. Meyaard, L. LAIR and collagens in immune regulation. Immunol. Lett. 128, 26-28 (2010).
22. del Rio, M. L., Lucas, C. L., Buhler, L., Rayat, G. & Rodriguez-Barbosa, J. I. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J. Leukoc. Biol. 87, 223-235 (2010).
23. Magis, C., van der Sloot, A. M., Serrano, L. & Notredame, C. An improved understanding of TNFL/TNFR interactions using structure-based classifications. Trends Biochem. Sci. 37, 353-363 (2012).
24. Croft, M. et al. TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol. 33, 144-152 (2012).
25. Sica, G. L. et al. RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NFκB. Blood 97, 2702-2707 (2001).
26. Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA4. Science 332, 600-603 (2011).
27. Zhu, Y., Yao, S. & Chen, L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 34, 466-478 (2011).
28. Cai, G. & Freeman, G. J. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating Tcell activation. Immunol. Rev. 229, 244-258 (2009).
29. Yao, S. et al. B7H2 is a costimulatory ligand for CD28 in human. Immunity 34, 729-740 (2011).
30. Yoshinaga, S. K. et al. Tcell costimulation through B7RP1 and ICOS. Nature 402, 827-832 (1999). (Pubitemid 129638129)
31. Wang, S. et al. Costimulation of T cells by B7H2, a B7like molecule that binds ICOS. Blood 96, 2808-2813 (2000).
32. Lin, D. Y. et al. The PD1/PDL1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl Acad. Sci. USA 105, 3011-3016 (2008). (Pubitemid 351723659)
33. Lazar-Molnar, E. et al. Crystal structure of the complex between programmed death1 (PD1) and its ligand PDL2. Proc. Natl Acad. Sci. USA 105, 10483-10488 (2008).
34. Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death1 ligand 1 interacts specifically with the B71 costimulatory molecule to inhibit T cell responses. Immunity 27, 111-122 (2007). (Pubitemid 47089023)
35. Park, J. J. et al. B7H1/CD80 interaction is required for the induction and maintenance of peripheral T cell tolerance. Blood 116, 1291-1298 (2010).
36. Eissner, G., Kolch, W. & Scheurich, P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 15, 353-366 (2004). (Pubitemid 39140699)
37. Munn, D. H., Sharma, M. D. & Mellor, A. L. Ligation of B71/B72 by human CD4+ T cells triggers indoleamine 2,3dioxygenase activity in dendritic cells. J. Immunol. 172, 4100-4110 (2004). (Pubitemid 38375222)
38. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008). (Pubitemid 351600389)
39. Azuma, T. et al. B7H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635-3643 (2008).
40. Flies, D. B., Wang, S., Xu, H. & Chen, L. Cutting edge: a monoclonal antibody specific for the programmed death1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 187, 1537-1541 (2011).
41. Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577-592 (2011).
42. Boomer, J. S. & Green, J. M. An enigmatic tail of CD28 signaling. Cold Spring Harb. Perspect. Biol. 2, a002436 (2010).
43. Janardhan, S. V., Praveen, K., Marks, R. & Gajewski, T. F. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS ONE 6, e24931 (2011).
44. Simpson, T. R., Quezada, S. A. & Allison, J. P. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr. Opin. Immunol. 22, 326-332 (2010).
45. Rudd, C. E. & Schneider, H. Unifying concepts in CD28, ICOS and CTLA4 coreceptor signalling. Nature Rev. Immunol. 3, 544-556 (2003). (Pubitemid 37328674)
46. Kroenke, M. A. et al. Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J. Immunol. 188, 3734-3744 (2012).
47. Choi, Y. S. et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity 34, 932-946 (2011).
48. Rudd, C. E., Taylor, A. & Schneider, H. CD28 and CTLA4 coreceptor expression and signal transduction. Immunol. Rev. 229, 12-26 (2009).
49. Knieke, K., Lingel, H., Chamaon, K. & Brunner-Weinzierl, M. C. Migration of Th1 lymphocytes is regulated by CD152 (CTLA4)-mediated signaling via PI3 kinase-dependent Akt activation. PLoS ONE 7, e31391 (2012).
50. Riley, J. L. PD1 signaling in primary T cells. Immunol. Rev. 229, 114-125 (2009).
51. Yokosuka, T. et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209, 1201-1217 (2012).
52. Yokosuka, T. et al. Spatiotemporal basis of CTLA4 costimulatory molecule-mediated negative regulation of T cell activation. Immunity 33, 326-339 (2010).
53. Sheppard, K. A. et al. PD1 inhibits Tcell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ. FEBS Lett. 574, 37-41 (2004).
54. Patsoukis, N. et al. Selective effects of PD1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal. 5, ra46 (2012).
55. Gavrieli, M., Watanabe, N., Loftin, S. K., Murphy, T. L. & Murphy, K. M. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP1 and SHP2. Biochem. Biophys. Res. Commun. 312, 1236-1243 (2003). (Pubitemid 37490949)
56. Gavrieli, M. & Murphy, K. M. Association of Grb2 and PI3K p85 with phosphotyrosile peptides derived from BTLA. Biochem. Biophys. Res. Commun. 345, 1440-1445 (2006). (Pubitemid 43817892)
57. Dong, Z. et al. The adaptor SAP controls NK cell activation by regulating the enzymes Vav1 and SHIP1 and by enhancing conjugates with target cells. Immunity 36, 974-985 (2012).
58. Cannons, J. L. et al. Biochemical and genetic evidence for a SAP-PKC-θ interaction contributing to IL4 regulation. J. Immunol. 185, 2819-2827 (2010).
59. Bloch-Queyrat, C. et al. Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn. J. Exp. Med. 202, 181-192 (2005). (Pubitemid 41002920)
60. Rangachari, M. et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim3mediated cell death and exhaustion. Nature Med. 18, 1394-1400 (2012).
61. Croft, M. The role of TNF superfamily members in Tcell function and diseases. Nature Rev. Immunol. 9, 271-285 (2009).
62. Croft, M. Costimulatory members of the TNFR family: keys to effective Tcell immunity? Nature Rev. Immunol. 3, 609-620 (2003). (Pubitemid 37328664)
63. Wang, C., Lin, G. H., McPherson, A. J. & Watts, T. H. Immune regulation by 41BB and 41BBL: complexities and challenges. Immunol. Rev. 229, 192-215 (2009).
64. Nocentini, G. & Riccardi, C. GITR: a modulator of immune response and inflammation. Adv. Exp. Med. Biol. 647, 156-173 (2009).
65. Xiao, X. et al. OX40 signaling favors the induction of TH9 cells and airway inflammation. Nature Immunol. 13, 981-990 (2012).
66. Podack, E. R., Strbo, N., Sotosec, V. & Muta, H. CD30governor of memory T cells? Ann. NY Acad. Sci. 975, 101-113 (2002).
67. Steinberg, M. W., Cheung, T. C. & Ware, C. F. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol. Rev. 244, 169-187 (2011).
68. Shui, J. W. et al. HVEM signalling at mucosal barriers provides host defence against pathogenic bacteria. Nature 488, 222-225 (2012).
69. Sakoda, Y. et al. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. Blood 117, 2506-2514 (2011).
70. Pobezinskaya, Y. L., Choksi, S., Morgan, M. J., Cao, X. & Liu, Z. G. The adaptor protein TRADD is essential for TNF-like ligand 1A/death receptor 3 signaling. J. Immunol. 186, 5212-5216 (2011).
71. Nolte, M. A., van Olffen, R. W., van Gisbergen, K. P. & van Lier, R. A. Timing and tuning of CD27CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 229, 216-231 (2009).
72. Shahinian, A. et al. Differential T cell costimulatory requirements in CD28deficient mice. Science 261, 609-612 (1993). (Pubitemid 23278372)
73. Meinl, E. et al. Differential requirement of ZAP70 for CD2mediated activation pathways of mature human T cells. J. Immunol. 165, 3578-3583 (2000). (Pubitemid 32057259)
74. Green, J. M., Karpitskiy, V., Kimzey, S. L. & Shaw, A. S. Coordinate regulation of T cell activation by CD2 and CD28. J. Immunol. 164, 3591-3595 (2000). (Pubitemid 30169811)
75. Denoeud, J. & Moser, M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J. Leukoc. Biol. 89, 195-203 (2011).
76. Linterman, M. A. et al. Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS. Immunity 30, 228-241 (2009).
77. Mizui, M. et al. Bimodal regulation of T cell-mediated immune responses by TIM4. Int. Immunol. 20, 695-708 (2008). (Pubitemid 351619237)
78. Cao, W., Ryan, M., Buckley, D., O'Connor, R. & Clarkson, M. R. Tim4 inhibition of Tcell activation and T helper type 17 differentiation requires both the immunoglobulin V and mucin domains and occurs via the mitogen-activated protein kinase pathway. Immunology 133, 179-189 (2011).
79. Xiao, L. et al. Suppression of allograft rejection by Tim1Fc through cross-linking with a novel Tim1 binding partner on T cells. PLoS ONE 6, e21697 (2011).
80. Meylan, F., Richard, A. C. & Siegel, R. M. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol. Rev. 244, 188-196 (2011).
81. Bour-Jordan, H. & Bluestone, J. A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 229, 41-66 (2009).
82. Xiao, X. et al. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo. J. Immunol. 188, 892-901 (2012).
83. Zeiser, R. et al. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood 109, 2225-2233 (2007). (Pubitemid 46348227)
84. Walker, L. S. & Sansom, D. M. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nature Rev. Immunol. 11, 852-863 (2011).
85. Tao, R., Wang, L., Murphy, K. M., Fraser, C. C. & Hancock, W. W. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J. Immunol. 180, 6649-6655 (2008).
86. Sharma, M. D. et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3dioxygenase. J. Clin. Invest. 117, 2570-2582 (2007). (Pubitemid 47494358)
87. Taylor, P. A. et al. B7 expression on T cells down-regulates immune responses through CTLA4 ligation via TT interactions. J. Immunol. 172, 34-39 (2004). (Pubitemid 38020452)
88. Paust, S., Lu, L., McCarty, N. & Cantor, H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc. Natl Acad. Sci. USA 101, 10398-10403 (2004). (Pubitemid 38924937)
89. Paterson, A. M. et al. The programmed death1 ligand 1, B71 pathway restrains diabetogenic effector T cells in vivo. J. Immunol. 187, 1097-1105 (2011).
90. Amarnath, S. et al. The PDL1PD1 axis converts human TH1 cells into regulatory T cells. Sci. Transl. Med. 3, 111ra120 (2011).
91. Amarnath, S. et al. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand1. PLoS Biol. 8, e1000302 (2010).
92. Franceschini, D. et al. PDL1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. 119, 551-564 (2009).
93. Francisco, L. M. et al. PDL1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015-3029 (2009).
94. Baitsch, L. et al. Extended coexpression of inhibitory receptors by human CD8 Tcells depending on differentiation, antigen-specificity and anatomical localization. PLoS ONE 7, e30852 (2012).
95. Boesteanu, A. C. & Katsikis, P. D. Memory T cells need CD28 costimulation to remember. Semin. Immunol. 21, 69-77 (2009).
96. Hendriks, J. et al. During viral infection of the respiratory tract, CD27, 41BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J. Immunol. 175, 1665-1676 (2005). (Pubitemid 41023070)
97. Zhu, Y., Zhu, G., Luo, L., Flies, A. S. & Chen, L. CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 109, 4882-4889 (2007). (Pubitemid 46827785)
98. Harlin, H., Podack, E., Boothby, M. & Alegre, M. L. TCR-independent CD30 signaling selectively induces IL13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. J. Immunol. 169, 2451-2459 (2002).
99. Redmond, W. L., Ruby, C. E. & Weinberg, A. D. The role of OX40mediated costimulation in Tcell activation and survival. Crit. Rev. Immunol. 29, 187-201 (2009).
100. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the antiCD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006). (Pubitemid 44343545)
101. Wherry, E. J. T cell exhaustion. Nature Immunol. 12, 492-499 (2011).
102. Antoine, P. et al. Functional exhaustion of CD4+ T lymphocytes during primary cytomegalovirus infection. J. Immunol. 189, 2665-2672 (2012).
103. Fourcade, J. et al. CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD1. Cancer Res. 72, 887-896 (2012).
104. Sakuishi, K., Jayaraman, P., Behar, S. M., Anderson, A. C. & Kuchroo, V. K. Emerging Tim3 functions in antimicrobial and tumor immunity. Trends Immunol. 32, 345-349 (2011).
105. Goldberg, M. V. & Drake, C. G. LAG3 in cancer immunotherapy. Curr. Top. Microbiol. Immunol. 344, 269-278 (2011).
106. Wang, C. et al. Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. J. Exp. Med. 209, 77-91 (2012).
107. Schwartz, R. H., Mueller, D. L., Jenkins, M. K. & Quill, H. Tcell clonal anergy. Cold Spring Harb. Symp. Quant. Biol. 54, 605-610 (1989).
108. Schwartz, R. H. T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2003). (Pubitemid 37174534)
109. McAfee, M. S. & Blattman, J. N. Combating chronic Tcell exhaustion. Immunotherapy 4, 557-560 (2012).
110. Fife, B. T. & Bluestone, J. A. Control of peripheral Tcell tolerance and autoimmunity via the CTLA4 and PD1 pathways. Immunol. Rev. 224, 166-182 (2008).
111. Takamura, S. et al. Premature terminal exhaustion of friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J. Immunol. 184, 4696-4707 (2010).
112. Angelosanto, J. M., Blackburn, S. D., Crawford, A. & Wherry, E. J. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J. Virol. 86, 8161-8170 (2012).
113. Angelosanto, J. M. & Wherry, E. J. Transcription factor regulation of CD8+ Tcell memory and exhaustion. Immunol. Rev. 236, 167-175 (2010).
114. Doering, T. A. et al. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 37, 1130-1144 (2012).
115. Lafferty, K. J. & Cunningham, A. J. A. New analysis of allogeneic interactions. J. Immunol. 112, 436-437 (1975).
116. Linsley, P. S., Clark, E. A. & Ledbetter, J. A. Tcell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB1. Proc. Natl Acad. Sci. USA 87, 5031-5035 (1990).
117. Linsley, P. S. et al. CTLA4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561-569 (1991).
118. Azuma, M. et al. B70 antigen is a second ligand for CTLA4 and CD28. Nature 366, 76-79 (1993). (Pubitemid 23345240)
119. Hathcock, K. S. et al. Identification of an alternative CTLA4 ligand costimulatory for T cell activation. Science 262, 905-907 (1993). (Pubitemid 24014079)
120. Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P. & Hodes, R. J. Comparative analysis of B71 and B72 costimulatory ligands: expression and function. J. Exp. Med. 180, 631-640 (1994). (Pubitemid 24224140)
121. Inaba, K. et al. The tissue distribution of the B72 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180, 1849-1860 (1994). (Pubitemid 24328575)
122. Saito, T. & Yamasaki, S. Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors. Immunol. Rev. 192, 143-160 (2003). (Pubitemid 36613330)
123. Fos, C. et al. ICOS ligation recruits the p50α PI3K regulatory subunit to the immunological synapse. J. Immunol. 181, 1969-1977 (2008).
124. Weiner, L. M., Surana, R. & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Rev. Immunol. 10, 317-327 (2010).
125. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
126. Linsley, P. S. & Nadler, S. G. The clinical utility of inhibiting CD28mediated costimulation. Immunol. Rev. 229, 307-321 (2009).
127. Larsen, C. P. et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443-453 (2005). (Pubitemid 40313335)
128. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252-264 (2012).
129. Topalian, S. L. et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
130. Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y. X. & Melero, I. Clinical experiences with antiCD137 and antiPD1 therapeutic antibodies. Semin. Oncol. 37, 508-516 (2010).
131. Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nature Rev. Cancer 12, 237-251 (2012).
132. Curran, K. J., Pegram, H. J. & Brentjens, R. J. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J. Gene Med. 14, 405-415 (2012).
133. Humphrey, R. W. et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J. Natl Cancer Inst. 103, 1222-1226 (2011).
134. Marabelle, A. & Caux, C. Immunobiology combined targeted and immunotherapy: the future of personalized medicine. Blood 120, 4454-4455 (2012).